- Home
- GCTK vs AZTR Comparison
GCTK vs AZTR Comparison
Compare GCTK & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTK
- AZTR
- Stock Information
- Founded
- GCTK 2001
- AZTR 2014
- Country
- GCTK United States
- AZTR United States
- Employees
- GCTK N/A
- AZTR N/A
- Industry
- GCTK Medical/Dental Instruments
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- GCTK Health Care
- AZTR Health Care
- Exchange
- GCTK Nasdaq
- AZTR Nasdaq
- Market Cap
- GCTK 3.3M
- AZTR 3.7M
- IPO Year
- GCTK N/A
- AZTR 2023
- Fundamental
- Price
- GCTK $4.49
- AZTR $0.76
- Analyst Decision
- GCTK
- AZTR
- Analyst Count
- GCTK 0
- AZTR 0
- Target Price
- GCTK N/A
- AZTR N/A
- AVG Volume (30 Days)
- GCTK 483.3K
- AZTR 7.5M
- Earning Date
- GCTK 08-14-2025
- AZTR 08-11-2025
- Dividend Yield
- GCTK N/A
- AZTR N/A
- EPS Growth
- GCTK N/A
- AZTR N/A
- EPS
- GCTK N/A
- AZTR N/A
- Revenue
- GCTK N/A
- AZTR N/A
- Revenue This Year
- GCTK N/A
- AZTR N/A
- Revenue Next Year
- GCTK N/A
- AZTR N/A
- P/E Ratio
- GCTK N/A
- AZTR N/A
- Revenue Growth
- GCTK N/A
- AZTR N/A
- 52 Week Low
- GCTK $4.22
- AZTR $0.70
- 52 Week High
- GCTK $3,756.00
- AZTR $4.45
- Technical
- Relative Strength Index (RSI)
- GCTK 38.42
- AZTR 34.80
- Support Level
- GCTK $4.70
- AZTR $0.90
- Resistance Level
- GCTK $5.88
- AZTR $1.09
- Average True Range (ATR)
- GCTK 0.46
- AZTR 0.15
- MACD
- GCTK 0.02
- AZTR 0.00
- Stochastic Oscillator
- GCTK 16.27
- AZTR 8.42
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.